fashion -WSS

fashion

author：entertainment 2025-09-28 21:06:40 - browse：4256

TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drugmakers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Over four hours, the debate spanned most of the substantive issues that pharmaceutical companies and their allies have raised across the country, both in constitutional challenges to the law and in challenges to how Medicare officials have interpreted the law so far. That means the court’s decision in these cases could produce a first substantive test for several of the arguments that haven’t been addressed by courts in other states, where companies like Boehringer Ingelheim, AstraZeneca, and Merck are also suing, separately, over the same law.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

explore

WSS

H5N1 bird flu: what we're starting to learn about infection in cows

New study raises questions about niacin and heart health

First recipient of genetically engineered pig kidney has died

Ukraine seeks to reclaim its role as a hub for clinical trials

H5N1 bird flu: what we're starting to learn about infection in cows

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

focus

fashion

entertainment

In age of alternative facts, a scholarly course on calling out crap

As AI regulations shape up, health tech startups beg for clarity

Walensky prepares to leave CDC — and Congress — behind

Telehealth startups turn to complex chronic diseases

Moonlake's readout produced a cash windfall. Risks remain

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Hepatitis C has a cure — but many Americans still lack access to it

FDA warns medical device makers about rise in fabricated data

After affirmative action ruling, medical educators look to 'holistic review'

Congress may force more Covid

hotspot

Ukraine seeks to reclaim its role as a hub for clinical trials

Readout LOUD podcast: What to know about H5N1 bird flu

Steward Health Care files for bankruptcy

Abridge raises $150m as clinical notes automation market heats up

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Telehealth startups turn to complex chronic diseases

explore

explore

hotspot

leisure time